WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

WuXi Biologics Included in S&P Global Sustainability Yearbook 2025

Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a...

Fosun Joins Hands with Abu Dhabi Investment Office, Adding New Momentum to Middle East Strategy

Fosun Joins Hands with Abu Dhabi Investment Office, Adding New Momentum to Middle East Strategy

HONG KONG and SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Fosun's global operations achieved another milestone. On February 20, during the Abu Dhabi Investment Forum in Shanghai, Fosun International signed a Memorandum of Strategic Cooperation with the...

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year

Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025...

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025...

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development,...

GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products

PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP) services, to...

menu
menu